Company / Capital Expenditures
Theravance Biopharma, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$42.0K
FY2025
5-year range
$42.0K / $6.6M
FY2021-FY2025
Trend
-87.3%
vs FY2024
Sector context
#179 of 194
Health Care
What the data says
Among 194 Health Care companies, Theravance Biopharma, Inc. is in the bottom 8% for capital expenditures. Capital Expenditures has declined for 3 consecutive years, from $7M in FY2022 to $42,000 in FY2025.
Based on SEC 10-K filings.
$42,000 in FY2025 with a 5-year CAGR of -63.6%.
Declined from $2M to $42,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -81.5%
- 5-Year CAGR
- -63.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 194This company $42.0K Sector average $117.5M
▼
-100.0% below sector average
Key checks
Key Insights
- Theravance Biopharma, Inc.'s capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of -63.6%, indicating a declining trend.
- In FY2025, capital expenditures decreased 87.3% year-over-year.
- Ranks #179 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $42.0K | -87.3% |
| FY2024 | $332.0K | -86.7% |
| FY2023 | $2.5M | -62.4% |
| FY2022 | $6.6M | +94.2% |
| FY2021 | $3.4M | -48.5% |
| FY2020 | $6.6M | +175.0% |
| FY2019 | $2.4M | +12.7% |
| FY2018 | $2.1M | -11.3% |
| FY2017 | $2.4M | +12.7% |
| FY2016 | $2.1M | -21.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026